Evotec SE to Announce First Quarter 2026 Results on May 6, 2026

April 29, 2026 1:50 AM

Evotec SE (NASDAQ:EVO; Frankfurt Prime Standard: EVT) will hold a webcast and conference call to announce its financial results for the first quarter 2026 and provide a business update on Wednesday, May 6, 2026. The conference call will be held in English.Webcast detailsDate: Wednesday, May 6, 2026Time: 2.00 pm CEST (12.00 pm GMT, 8.00 am EDT)To join the audio webcast and to access the presentation slides, please register via this link.The...

Read more

Capstone Family Medicine and Alaska Provider Network Lead First-of-Its-Kind Partnership to Transform Rural Healthcare Delivery

April 28, 2026 6:30 PM

Capstone Family Medicine (Capstone), the state's largest rural private practice in primary care, in close collaboration with Alaska Provider Network (APN), today announced a first-of-its-kind strategic partnership with a coalition of national and regional leaders to redefine healthcare delivery across rural Alaska.This alliance includes Electronic Caregiver, Pinnacle Integrated Medicine, Pinnacle Resource Management, Pearl Health, Kachemak...

Read more

Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

April 28, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release dated April 21, 2026, the successful scale-up of key intermediates1 A83 and B4, representing an advancement in the Company's chemistry, manufacturing and controls (CMC) program supporting its lead nanoparticle-based PNKP inhibitor drug candidate, ONC010 (also referred to as PNKP Inhibitor Technology)....

Read more

Mindologi Expands Nationwide, Reaching Nearly 500 Providers, as Patent-Pending Platform Advances Mental Health Clarity

April 28, 2026 12:20 PM

Mindologi announced its nationwide expansion within one month of its launch on January 15, 2026, marking a significant early milestone in its rapid growth. The platform expanded across the United States shortly after launch and now works with nearly 500 licensed providers. This early traction reflects increasing demand for faster, more structured pathways to understanding mental health symptoms and accessing appropriate care.Mindologi LogoThe...

Read more

Dr. Denaesh Ariyanayagam Calls for Greater Focus on Patient Advocacy and Medical Excellence

April 28, 2026 10:40 AM

Dr. Denaesh Ariyanayagam, a Consultant General and Vascular Surgeon at St. Augustine Private Hospital, is raising awareness around the critical need for patient advocacy, consistent medical standards, and long-term professional discipline in healthcare. With decades of experience in surgery, education, and hospital leadership, Dr. Ariyanayagam is emphasizing that strong healthcare systems begin with individual accountability and a clear focus on...

Read more

Global Nurse Migration Patterns Shift as Europe, Southeast Asia Absorb Growing Share of International Nurses

April 28, 2026 10:00 AM

TruMerit™ (formerly CGFNS International) today released its 2025 Nurse Migration Report, revealing significant shifts in global nurse migration patterns and widening inequities in nursing workforce distribution across regions with vastly different healthcare needs.The report, which analyzes World Health Organization data and TruMerit's proprietary VisaScreen® application records, shows that international nurse migration flows are increasingly...

Read more

Protagonist Exercises Rusfertide U.S. Opt-Out Right Under Takeda Collaboration

April 28, 2026 9:05 AM

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) ("Protagonist" or the "Company") today announced that it has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under its worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera...

Read more

Revecore Launches AI-Powered Underpayment Recovery and Denial Appeals Capabilities

April 28, 2026 9:03 AM

Revecore, a leading provider of complex revenue cycle management solutions for hospital systems nationwide, today announced new AI-powered capabilities across underpayment recovery and denial appeals. The announcement comes as hospitals spent nearly $18 billion in 2025 on overturning claims denials alone, according to the American Hospital Association, with no sign the pressure is easing. As health systems navigate rising denial rates, growing...

Read more

CVS Health: What's Next in Treatment: Four Drugs That Could Change Care This Spring

April 28, 2026 9:00 AM

Originally published on CVS Health Company NewsNew treatments take years of research, clinical trials, and regulatory review before reaching patients. Several therapies approaching FDA decisions this spring could expand treatment options for people managing a range of conditions.CVS Caremark's Clinical Pipeline Services team - made up of licensed clinical pharmacists and analysts - monitors new therapies moving through the drug pipeline and...

Read more

Glidewell Expands Next-Day Crown Service to BruxZir(R) Esthetic

April 28, 2026 9:00 AM

The Next-Day service from Glidewell is expanding to include BruxZir® Esthetic. Now, this service delivers the leading esthetic monolithic zirconia restoration to dental offices in as little as 21 hours after scan submission. Next-Day BruxZir Esthetic gives dentists access to beautiful crowns and bridges ready to seat tomorrow."Dentists across the U.S. now rely on our Next-Day BruxZir Full-Strength service, not just for emergency cases, but also...

Read more

LayerBio Announces FDA Acceptance of Investigational New Drug (IND) Application for OcuRing-K, a Sustained-Release Ketorolac Implant for Cataract Surgery Patients

April 28, 2026 8:50 AM

LayerBio, a clinical-stage biotechnology company developing sustained-release ophthalmic therapies, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for OcuRing-K™, an intraocular implant designed to deliver therapeutic levels of ketorolac directly within the eye following cataract surgery.OcuRing-K is a proprietary implant formulation engineered to provide sustained,...

Read more

MDaudit Launches "Revenue Integrity Redefined" Campaign to Help Healthcare Organizations Reclaim Financial Control

April 28, 2026 8:00 AM

Revenue risk no longer begins and ends with managing denials. It now touches every stage of the revenue cycle - from documentation, charge capture, and coding to billing and denials management - and healthcare organizations relying on reactive, manual, and siloed oversight approaches are paying the price. In an environment defined by financial pressure, heightened regulatory scrutiny, and increasingly AI-powered payer behavior, reactive...

Read more

Black Book Releases 2026 State of Digital Healthcare Technology in Accountable Care Organizations eBook

April 28, 2026 7:15 AM

Black Book Research today released its new industry eBook, The 2026 State of Digital Healthcare Technology in Accountable Care Organizations, examining how accountable care organizations are modernizing digital infrastructure as downside risk, quality measurement, payer interoperability, prior authorization automation, and care orchestration intensify across the ACO market.The report is available at no charge to healthcare industry stakeholders...

Read more

Independent Medical Practices Face Mounting Pressure as Medicare Reimbursement Strains Traditional Care Models

April 28, 2026 5:10 AM

Independent medical practices in markets such as Huntsville are entering a period of growing strain as Medicare reimbursement continues to challenge traditional care models, prompting providers to rethink how community-based healthcare can remain viable in the years ahead.Discovery Medical Center says the pressure is contributing to a widening divide between practices built primarily around reimbursement and those developing more diversified...

Read more

SphingoTec Introduces ELISA sphingotest(R) penKid(R) to Enable Broad Kidney Biomarker Testing for Research Applications

April 28, 2026 3:10 AM

SphingoTec GmbH announces the launch of the ELISA sphingotest® penKid®, a new assay designed to make testing of its proprietary biomarker broadly accessible to research laboratories and pharmaceutical partners. Providing ease-of-use and precision, the test facilitates large-scale investigations of human kidney function in both acute and broader clinical research contexts.Responding to growing research interestThe launch follows increasing demand...

Read more

BioNxt Applies Advanced Drug Delivery Strategy and Psychedelic Compound Library to Emerging Therapeutics Market Amid Accelerating Global Momentum

April 28, 2026 3:05 AM

BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to announce that it is evaluating opportunities to apply its proprietary drug delivery technologies to the emerging field of psychedelic therapeutics in response to accelerating regulatory, clinical, and policy momentum globally.Recent developments in the United States, including...

Read more

iZafe Group Q1 Interim Report, January-March 2026

April 28, 2026 2:50 AM

iZafe Group (STO:IZAFE-B) - iZafe Group AB (publ.) presents today, April 28th, its report for the first quarter.Financial Performance in SummaryThe Group's total net sales for the quarter amounted to 2,419 (1,318) TSEK and consisted entirely of recurring license revenues, with no hardware sales during the period. Compared to the corresponding quarter of the previous year, the development reflects the Company's established business model focused...

Read more

Genflow Biosciences PLC Announces Expansion of Confidentiality Agreements

April 28, 2026 2:00 AM

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or the "Company"), a biotechnology company focused on the development of gene therapies for age-related diseases announces the expansion of its engagement with participants in the global animal health sector.Following the positive preliminary interim results reported in an RNS on February 12, 2026 and the initial execution of confidentiality agreements, the Company has entered into...

Read more

Hemogenyx Pharmaceuticals PLC Announces Institutional Fundraise

April 28, 2026 2:00 AM

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce that it has raised £3,000,000 from a small group of institutional investors to support the acceleration of its clinical development programmes. The fundraising was completed through a direct subscription for 374,532 new ordinary shares in the Company at a market bid price at closing of trading on April 27 of £8.01 per share.The net proceeds from the fundraising will be used...

Read more

Recovery Beach Reopens With New Executive Director After Renovation

April 27, 2026 6:35 PM

Recovery Beach, a premier detox and residential treatment facility near Anaheim, California, is reopening April 27th with a new Executive Director, improved clinical offerings, and a renovated facility. New ownership facilitated these defining moves, which are set to reinvigorate an already successful addiction recovery program.Dr. Kenyota Dokes, a former psychotherapist turned executive, is Recovery Beach's new Executive Director. Known for...

Read more